

Giuseppe Altavilla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8679261/publications.pdf>

Version: 2024-02-01

29
papers

5,499
citations

623734

14
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

7181
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246. | 10.7 | 4,943 |
| 2 | Liquid biopsy for lung cancer early detection. <i>Journal of Thoracic Disease</i> , 2018, 10, S882-S897. | 1.4 | 93 |
| 3 | Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 109-125. | 2.7 | 49 |
| 4 | Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. <i>Translational Lung Cancer Research</i> , 2015, 4, 728-42. | 2.8 | 48 |
| 5 | DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 556-563. | 2.0 | 35 |
| 6 | Recent developments in the use of immunotherapy in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 781-798. | 2.5 | 29 |
| 7 | A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. <i>Translational Lung Cancer Research</i> , 2021, 10, 1536-1556. | 2.8 | 28 |
| 8 | Targeted drugs in small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 51-70. | 2.8 | 28 |
| 9 | Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2047-2063. | 4.3 | 26 |
| 10 | Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases. <i>Journal of Neuro-Oncology</i> , 2008, 90, 31-33. | 2.9 | 25 |
| 11 | Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 413-424. | 2.5 | 24 |
| 12 | Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 255-268. | 2.5 | 24 |
| 13 | Feasibility of cell-free circulating tumor DNA testing for lung cancer. <i>Biomarkers in Medicine</i> , 2016, 10, 417-430. | 1.4 | 21 |
| 14 | Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 713-722. | 4.1 | 17 |
| 15 | Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC). <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 406-415. | 1.2 | 16 |
| 16 | Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. <i>SpringerPlus</i> , 2014, 3, 123. | 1.2 | 12 |
| 17 | Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study. <i>Supportive Care in Cancer</i> , 2018, 26, 4021-4029. | 2.2 | 12 |
| 18 | High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data. <i>In Vivo</i> , 2020, 34, 2009-2014. | 1.3 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 469-479. | 2.5 | 11 |
| 20 | Immunotherapeutic Advances for NSCLC. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 399-417. | 3.2 | 9 |
| 21 | Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications. <i>Epigenomics</i> , 2016, 8, 1151-1167. | 2.1 | 8 |
| 22 | Thyroid function, autoimmunity and nodules in hematological malignancies. <i>Archives of Endocrinology and Metabolism</i> , 2015, 59, 236-244. | 0.6 | 6 |
| 23 | Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S329-S333. | 2.8 | 6 |
| 24 | Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer. <i>Journal of Dermatological Treatment</i> , 2016, 27, 148-152. | 2.2 | 5 |
| 25 | Capillary leak syndrome induced by neoadjuvant cisplatin and gemcitabine in a patient with bladder cancer. <i>Urology Case Reports</i> , 2021, 34, 101461. | 0.3 | 5 |
| 26 | Nail toxicities induced by liposomal doxorubicin: a retrospective case series. <i>European Journal of Dermatology</i> , 2017, 27, 434-435. | 0.6 | 2 |
| 27 | Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy. <i>Clinical Drug Investigation</i> , 2018, 38, 269-278. | 2.2 | 2 |
| 28 | Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma. <i>Dermatologic Therapy</i> , 2020, 33, e14417. | 1.7 | 2 |
| 29 | Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome. <i>BJR case Reports</i> , 2019, 5, 20190064. | 0.2 | 0 |